In this issue:
- Regional variation in cardiac implantable electronic device implants in NZ
- Bleeding risk with rivaroxaban vs vitamin K antagonists in the elderly
- Alcohol consumption in patients with AF
- Cardiac myosin activation with omecamtiv mecarbil in systolic HF
- Effect of obesity on response to spironolactone in patients with HFpEF
- Interleukin-1 receptor antagonist rilonacept in recurrent pericarditis
- Myocardial remodelling after withdrawal of HF therapy in patients with recovered DCM
- Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole
- Effects of PFO occluder device in patients with PFO and migraine
- Efficacy of alirocumab after ACS according to achieved LDL cholesterol level
- Silent brain infarcts and cognitive outcomes after TAVI
- Short-term DAPT followed by P2Y12 inhibitor vs prolonged DAPT after PCI with DES
- Cardiovascular polypill in individuals without cardiovascular disease
- ACE inhibitors and ARBs in patients hospitalised with COVID-19
Please login below to download this issue (PDF)